227 related articles for article (PubMed ID: 27313208)
1. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
2. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
4. NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.
Führer S; Ahammer L; Ausserbichler A; Scheffzek K; Dunzendorfer-Matt T; Tollinger M
Biomol NMR Assign; 2017 Oct; 11(2):305-308. PubMed ID: 28831766
[TBL] [Abstract][Full Text] [Related]
5. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
[TBL] [Abstract][Full Text] [Related]
6. SPRED proteins provide a NF-ty link to Ras suppression.
McClatchey AI; Cichowski K
Genes Dev; 2012 Jul; 26(14):1515-9. PubMed ID: 22802525
[TBL] [Abstract][Full Text] [Related]
7. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
[TBL] [Abstract][Full Text] [Related]
8. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
9. Merlin cooperates with neurofibromin and Spred1 to suppress the Ras-Erk pathway.
Cui Y; Ma L; Schacke S; Yin JC; Hsueh YP; Jin H; Morrison H
Hum Mol Genet; 2021 Feb; 29(23):3793-3806. PubMed ID: 33331896
[TBL] [Abstract][Full Text] [Related]
10. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.
Siljamäki E; Abankwa D
Mol Cell Biol; 2016 Oct; 36(20):2612-25. PubMed ID: 27503857
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.
Yunoue S; Tokuo H; Fukunaga K; Feng L; Ozawa T; Nishi T; Kikuchi A; Hattori S; Kuratsu J; Saya H; Araki N
J Biol Chem; 2003 Jul; 278(29):26958-69. PubMed ID: 12730209
[TBL] [Abstract][Full Text] [Related]
13. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
[TBL] [Abstract][Full Text] [Related]
14. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
15. The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1 mice.
Ismat FA; Xu J; Lu MM; Epstein JA
J Clin Invest; 2006 Sep; 116(9):2378-84. PubMed ID: 16906226
[TBL] [Abstract][Full Text] [Related]
16. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.
Cichowski K; Santiago S; Jardim M; Johnson BW; Jacks T
Genes Dev; 2003 Feb; 17(4):449-54. PubMed ID: 12600938
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis of the GAP-related domain from neurofibromin and its implications.
Scheffzek K; Ahmadian MR; Wiesmüller L; Kabsch W; Stege P; Schmitz F; Wittinghofer A
EMBO J; 1998 Aug; 17(15):4313-27. PubMed ID: 9687500
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.
Mangoura D; Sun Y; Li C; Singh D; Gutmann DH; Flores A; Ahmed M; Vallianatos G
Oncogene; 2006 Feb; 25(5):735-45. PubMed ID: 16314845
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.
Sherekar M; Han SW; Ghirlando R; Messing S; Drew M; Rabara D; Waybright T; Juneja P; O'Neill H; Stanley CB; Bhowmik D; Ramanathan A; Subramaniam S; Nissley DV; Gillette W; McCormick F; Esposito D
J Biol Chem; 2020 Jan; 295(4):1105-1119. PubMed ID: 31836666
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders.
Borrie SC; Plasschaert E; Callaerts-Vegh Z; Yoshimura A; D'Hooge R; Elgersma Y; Kushner SA; Legius E; Brems H
Mol Autism; 2021 Jul; 12(1):53. PubMed ID: 34311771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
